Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer

ObjectivesTo determine the integrative value of clinical, hematological, and computed tomography (CT) radiomic features in survival prediction for locally advanced non-small cell lung cancer (LA-NSCLC) patients.MethodsRadiomic features and clinical and hematological features of 118 LA-NSCLC cases were firstly extracted and analyzed in this study. Then, stable and prognostic radiomic features were automatically selected using the consensus clustering method with either Cox proportional hazard (CPH) model or random survival forest (RSF) analysis. Predictive radiomic, clinical, and hematological parameters were subsequently fitted into a final prognostic model using both the CPH model and the RSF model. A multimodality nomogram was then established from the fitting model and was cross-validated. Finally, calibration curves were generated with the predicted versus actual survival status.ResultsRadiomic features selected by clustering combined with CPH were found to be more predictive, with a C-index of 0.699 in comparison to 0.648 by clustering combined with RSF. Based on multivariate CPH model, our integrative nomogram achieved a C-index of 0.792 and retained 0.743 in the cross-validation analysis, outperforming radiomic, clinical, or hematological model alone. The calibration curve showed agreement between predicted and actual values for the 1-year and 2-year survival prediction. Interestingly, the selected important radiomic features were significantly correlated with levels of platelet, platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) (p values all < 0.05).ConclusionsThe integrative nomogram incorporated CT radiomic, clinical, and hematological features improved survival prediction in LA-NSCLC patients, which would offer a feasible and practical reference for individualized management of these patients.Key Points• An integrative nomogram incorporated CT radiomic, clinical, and hematological features was constructed and cross-validated to predict prognosis of LA-NSCLC patients.• The integrative nomogram outperformed radiomic, clinical, or hematological model alone.• This nomogram has value to permit non-invasive, comprehensive, and dynamical evaluation of the phenotypes of LA-NSCLC and can provide a feasible and practical reference for individualized management of LA-NSCLC patients.

[1]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[3]  P. Lambin,et al.  Radiomics: the bridge between medical imaging and personalized medicine , 2017, Nature Reviews Clinical Oncology.

[4]  Xinxiang Li,et al.  Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection , 2016, International Journal of Cancer.

[5]  Lisheng Wang,et al.  A topo-graph model for indistinct target boundary definition from anatomical images , 2018, Comput. Methods Programs Biomed..

[6]  Cynthia S. Johnson,et al.  Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Rafael Sirera,et al.  The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Yanqi Huang,et al.  Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. , 2016, Radiology.

[9]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[10]  P. Iyengar,et al.  Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Ying Sun,et al.  Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. , 2018, The Lancet. Oncology.

[12]  M. Hatt,et al.  Erratum to: Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I–III , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  B. Kong,et al.  Development and Validation of a Deep Learning Radiomics Model Predicting Lymph Node Status in Operable Cervical Cancer , 2020, Frontiers in Oncology.

[14]  Walter H Backes,et al.  CT texture analysis in colorectal liver metastases: A better way than size and volume measurements to assess response to chemotherapy? , 2016, United European gastroenterology journal.

[15]  G. Veronesi,et al.  FDG PET/CT as theranostic imaging in diagnosis of non-small cell lung cancer. , 2017, Frontiers in bioscience.

[16]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[17]  Joseph O. Deasy,et al.  A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients , 2015, International journal of radiation oncology, biology, physics.

[18]  Thomas A Gerds,et al.  Estimating a time‐dependent concordance index for survival prediction models with covariate dependent censoring , 2013, Statistics in medicine.

[19]  Fenghai Duan,et al.  Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Peter Balter,et al.  Delta-radiomics features for the prediction of patient outcomes in non–small cell lung cancer , 2017, Scientific Reports.

[21]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[22]  T. Coroller,et al.  Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC. , 2016, Lung cancer.

[23]  P. Lambin,et al.  Defining the biological basis of radiomic phenotypes in lung cancer , 2017, eLife.

[24]  Jill S. Barnholtz-Sloan,et al.  EPID-08. EPIDEMIOLOGY OF GERM CELL TUMORS IN THE CENTRAL NERVOUS SYSTEM , 2017 .

[25]  Yibin Kang,et al.  The metastasis-promoting roles of tumor-associated immune cells , 2013, Journal of Molecular Medicine.

[26]  P. Maxim,et al.  Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer , 2016, PloS one.

[27]  Ruijiang Li,et al.  A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer. , 2018, International journal of radiation oncology, biology, physics.

[28]  C. Garlanda,et al.  Tumor associated macrophages and neutrophils in tumor progression , 2013, Journal of cellular physiology.

[29]  C. Haie-meder,et al.  A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  Jeffrey D Bradley,et al.  Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non–Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235 , 2016, The Journal of Nuclear Medicine.

[31]  N. Bhooshan,et al.  Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. , 2017, The oncologist.

[32]  Y. Wu,et al.  Preoperative platelet count in predicting lymph node metastasis and prognosis in patients with non-small cell lung cancer. , 2013, Neoplasma.

[33]  S. Armato,et al.  Lung texture in serial thoracic computed tomography scans: correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development. , 2015, International journal of radiation oncology, biology, physics.

[34]  M. Eble,et al.  Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  Ralph A Bundschuh,et al.  Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy , 2015, Radiation oncology.

[36]  Florent Tixier,et al.  Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I–III , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  Steffen Löck,et al.  A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling , 2017, Scientific Reports.

[38]  K. O'Byrne,et al.  Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. , 2000, Lung cancer.

[39]  J. Herndon,et al.  Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[41]  S. Thibodeau,et al.  Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. , 2005, Chest.

[42]  Yong Yin,et al.  Topology polymorphism graph for lung tumor segmentation in PET-CT images , 2015, Physics in medicine and biology.

[43]  Devin Tian,et al.  An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825 , 2016, Neuro-oncology.

[44]  M. Hatt,et al.  18F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi–Cancer Site Patient Cohort , 2015, The Journal of Nuclear Medicine.